BR112017020408A2 - ?biotinas e composições? - Google Patents
?biotinas e composições?Info
- Publication number
- BR112017020408A2 BR112017020408A2 BR112017020408A BR112017020408A BR112017020408A2 BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2 BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2
- Authority
- BR
- Brazil
- Prior art keywords
- biotins
- compositions
- nmo
- biotin
- treatment
- Prior art date
Links
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 150000001615 biotins Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
- Magnetic Ceramics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020408A2 true BR112017020408A2 (pt) | 2018-06-05 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020408A BR112017020408A2 (pt) | 2015-03-26 | 2016-03-25 | ?biotinas e composições? |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10357480B2 (enExample) |
| EP (2) | EP3072513A1 (enExample) |
| JP (1) | JP6752874B2 (enExample) |
| KR (1) | KR20170131543A (enExample) |
| CN (2) | CN111973592A (enExample) |
| AU (1) | AU2016238759B2 (enExample) |
| BR (1) | BR112017020408A2 (enExample) |
| CA (1) | CA2980660A1 (enExample) |
| CY (1) | CY1122374T1 (enExample) |
| DK (1) | DK3273957T3 (enExample) |
| EA (1) | EA034394B1 (enExample) |
| ES (1) | ES2748354T3 (enExample) |
| HR (1) | HRP20191491T1 (enExample) |
| HU (1) | HUE046116T2 (enExample) |
| IL (1) | IL254619B (enExample) |
| LT (1) | LT3273957T (enExample) |
| MA (1) | MA41809B1 (enExample) |
| ME (1) | ME03567B (enExample) |
| PL (1) | PL3273957T3 (enExample) |
| PT (1) | PT3273957T (enExample) |
| RS (1) | RS59149B1 (enExample) |
| SI (1) | SI3273957T1 (enExample) |
| SM (1) | SMT201900548T1 (enExample) |
| WO (1) | WO2016151132A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| EP3893823A4 (en) * | 2018-12-11 | 2022-11-02 | Myospots Australia Pty Ltd | Adhesive pad |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| EP4225327A4 (en) * | 2020-10-09 | 2024-10-16 | TX Medic AB | TREATMENT OF MUSCLE ATROPHY WITH DEXTRAN SULFATE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| PL377612A1 (pl) | 2002-09-27 | 2006-02-06 | Biogen Idec Ma Inc. | Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| FR2993780B1 (fr) * | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| WO2012145746A1 (en) * | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| KR101951220B1 (ko) * | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| WO2014177286A1 (en) | 2013-04-29 | 2014-11-06 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en not_active Ceased
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018006471A2 (pt) | compostos úteis como moduladores de trpm8 | |
| BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| BR112018010118A2 (pt) | inibidores de cxcr2 | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201692219A1 (ru) | Способы получения противовирусных соединений | |
| BR112016002391A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| MX2016011072A (es) | Derivado de pirazol amida. | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| MX2017007377A (es) | Compuestos organicos. | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
| CL2016001349A1 (es) | Uso de derivados de bencimidazol-prolina | |
| CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων | |
| BR112017008481A2 (pt) | composto antimicótico | |
| BR112017018834A2 (pt) | variantes de protoxina-ii e métodos de uso | |
| MX373603B (es) | Activador de canales de kcnq2-5. | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| NZ730092A (en) | Use of cysteamine in treating infections caused by yeasts/moulds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |